User login
Physician innovator working to bring new tech to patients, thanks to AGA funding
The AGA Research Foundation’s career development awards are invaluable tools for early career investigators to advance their careers in gastroenterology and hepatology research. When Ashish Nimgaonkar, MD, MTech, MS, received the AGA-Boston Scientific Career Development Technology and Innovation Award in 2014, he was able to step up his research and develop a new technological approach for managing patients with chronic liver disease-related complications. We are delighted to introduce you to the work of Dr. Nimgaonkar, medical director in the Johns Hopkins Center for Bioengineering Innovation and Design, department of biomedical engineering, and an assistant professor of medicine and business at Johns Hopkins University.
When Dr. Nimgaonkar received his funding from the AGA Research Foundation in 2014, he was able to focus on developing a technology that would enable patients with refractory ascites to manage their condition at home. This is a condition in which a large volume of fluid accumulates in the abdomen, causes difficulty breathing and affects patients’ quality of life. Patients visit a hospital or clinic several times a month to drain the fluid, which could weigh as much as 10 pounds or more. Refractory ascites is stubbornly resistant to standard medical therapy. The only definitive treatment is liver transplantation.
Dr. Nimgaonkar was able to combine his dual training in gastroenterology and in medical technology innovation through the biodesign program at Stanford University, along with the breadth of engineering and research expertise at Johns Hopkins University, to develop a bio-powered shunt that moves a patient’s fluid buildup out of the peritoneal cavity to the urinary bladder, where it can be eliminated naturally. His shunt has another major advantage for patients who are on liver transplant lists and are required to undergo MRI and other diagnostics: it contains no metal components.
Read more and get to know Ashish Nimgaonkar, MD, MTech, MS by visiting:
https://www.gastro.org/news/physician-innovator-working-to-bring-new-tech-to-patients-thanks-to-aga-funding
Help AGA build a community of investigators through the AGA Research Foundation.
Your donation to the AGA Research Foundation can fund future success stories by keeping young scientists working to advance our understanding of digestive diseases. Donate today at www.gastro.org/donateonline.
The AGA Research Foundation’s career development awards are invaluable tools for early career investigators to advance their careers in gastroenterology and hepatology research. When Ashish Nimgaonkar, MD, MTech, MS, received the AGA-Boston Scientific Career Development Technology and Innovation Award in 2014, he was able to step up his research and develop a new technological approach for managing patients with chronic liver disease-related complications. We are delighted to introduce you to the work of Dr. Nimgaonkar, medical director in the Johns Hopkins Center for Bioengineering Innovation and Design, department of biomedical engineering, and an assistant professor of medicine and business at Johns Hopkins University.
When Dr. Nimgaonkar received his funding from the AGA Research Foundation in 2014, he was able to focus on developing a technology that would enable patients with refractory ascites to manage their condition at home. This is a condition in which a large volume of fluid accumulates in the abdomen, causes difficulty breathing and affects patients’ quality of life. Patients visit a hospital or clinic several times a month to drain the fluid, which could weigh as much as 10 pounds or more. Refractory ascites is stubbornly resistant to standard medical therapy. The only definitive treatment is liver transplantation.
Dr. Nimgaonkar was able to combine his dual training in gastroenterology and in medical technology innovation through the biodesign program at Stanford University, along with the breadth of engineering and research expertise at Johns Hopkins University, to develop a bio-powered shunt that moves a patient’s fluid buildup out of the peritoneal cavity to the urinary bladder, where it can be eliminated naturally. His shunt has another major advantage for patients who are on liver transplant lists and are required to undergo MRI and other diagnostics: it contains no metal components.
Read more and get to know Ashish Nimgaonkar, MD, MTech, MS by visiting:
https://www.gastro.org/news/physician-innovator-working-to-bring-new-tech-to-patients-thanks-to-aga-funding
Help AGA build a community of investigators through the AGA Research Foundation.
Your donation to the AGA Research Foundation can fund future success stories by keeping young scientists working to advance our understanding of digestive diseases. Donate today at www.gastro.org/donateonline.
The AGA Research Foundation’s career development awards are invaluable tools for early career investigators to advance their careers in gastroenterology and hepatology research. When Ashish Nimgaonkar, MD, MTech, MS, received the AGA-Boston Scientific Career Development Technology and Innovation Award in 2014, he was able to step up his research and develop a new technological approach for managing patients with chronic liver disease-related complications. We are delighted to introduce you to the work of Dr. Nimgaonkar, medical director in the Johns Hopkins Center for Bioengineering Innovation and Design, department of biomedical engineering, and an assistant professor of medicine and business at Johns Hopkins University.
When Dr. Nimgaonkar received his funding from the AGA Research Foundation in 2014, he was able to focus on developing a technology that would enable patients with refractory ascites to manage their condition at home. This is a condition in which a large volume of fluid accumulates in the abdomen, causes difficulty breathing and affects patients’ quality of life. Patients visit a hospital or clinic several times a month to drain the fluid, which could weigh as much as 10 pounds or more. Refractory ascites is stubbornly resistant to standard medical therapy. The only definitive treatment is liver transplantation.
Dr. Nimgaonkar was able to combine his dual training in gastroenterology and in medical technology innovation through the biodesign program at Stanford University, along with the breadth of engineering and research expertise at Johns Hopkins University, to develop a bio-powered shunt that moves a patient’s fluid buildup out of the peritoneal cavity to the urinary bladder, where it can be eliminated naturally. His shunt has another major advantage for patients who are on liver transplant lists and are required to undergo MRI and other diagnostics: it contains no metal components.
Read more and get to know Ashish Nimgaonkar, MD, MTech, MS by visiting:
https://www.gastro.org/news/physician-innovator-working-to-bring-new-tech-to-patients-thanks-to-aga-funding
Help AGA build a community of investigators through the AGA Research Foundation.
Your donation to the AGA Research Foundation can fund future success stories by keeping young scientists working to advance our understanding of digestive diseases. Donate today at www.gastro.org/donateonline.
Washington makes low drug prices a priority
The House of Representatives passed two bills aimed at speeding up the development of generics and biosimilars while the Trump administration finalized a rule to require drug companies to list the price of their products in their television ads.
The House passed two bills to address drug pricing. The House passed H.R. 1503, the Orange Book Transparency Act of 2019, legislation that would make changes to the FDA’s “orange” book to provide better information on brand drug and patent exclusivity. The orange book is used by doctors and pharmacists for information on generic drug approvals and availability. It is also used by generic drug manufacturers to make decisions on where to invest in research and development as it provides information on the exclusivity period for brand name drugs. Similarly, the House passed H.R. 1520, the Purple Book Continuity Act, legislation that would update FDA’s “purple” book on patents and exclusivity for biologics. These are the first bills of the 116th Congress to pass that address the costs of drugs.
The Administration finalizes rule on drug costs in advertising. The Trump administration finalized a rule that would require drug manufacturers to disclose prices on their products in television advertisements. Manufacturers must list a product’s monthly wholesale price or the cost of a typical treatment if it is greater than $35 for 30 days. The information must appear in text large enough for people to read it and should also include a statement that people with insurance may pay a different amount for the product. The rule takes effect in 60 days and the drug industry opposes the rule, which they say could sway patients away from certain medications and lead to more misinformation on the actual costs.
House Appropriations Committee approves $2 billion NIH increase. The House Appropriations Committee approved their fiscal year 2020 Labor, HHS, and Education Appropriations bill that includes a $2 billion increase in NIH funding. The Committee also includes critical report language on several GI research areas including inflammatory bowel disease, colorectal cancer screenings, early onset colorectal cancer, and the role of food as medicine in treating diseases. The bill also includes important language directing CMS to require Medicare Advantage plans to exclude from prior authorization requirements those services that align with evidence-based guidelines and have a high prior authorization approval rate. The language also calls for more transparency for MA plans with prior authorization so physicians are aware of what services require it.
Medical Nutrition Equity Act introduced in House. Rep. Jim McGovern, D-Mass., introduced H.R. 2501, the Medical Nutrition Equity Act, legislation that would mandate coverage of medically necessary foods for individuals with digestive and inherited metabolic disorders. AGA is supportive of this legislation that is critical for patients with digestive diseases and ensures their access to these lifesaving products.
The House of Representatives passed two bills aimed at speeding up the development of generics and biosimilars while the Trump administration finalized a rule to require drug companies to list the price of their products in their television ads.
The House passed two bills to address drug pricing. The House passed H.R. 1503, the Orange Book Transparency Act of 2019, legislation that would make changes to the FDA’s “orange” book to provide better information on brand drug and patent exclusivity. The orange book is used by doctors and pharmacists for information on generic drug approvals and availability. It is also used by generic drug manufacturers to make decisions on where to invest in research and development as it provides information on the exclusivity period for brand name drugs. Similarly, the House passed H.R. 1520, the Purple Book Continuity Act, legislation that would update FDA’s “purple” book on patents and exclusivity for biologics. These are the first bills of the 116th Congress to pass that address the costs of drugs.
The Administration finalizes rule on drug costs in advertising. The Trump administration finalized a rule that would require drug manufacturers to disclose prices on their products in television advertisements. Manufacturers must list a product’s monthly wholesale price or the cost of a typical treatment if it is greater than $35 for 30 days. The information must appear in text large enough for people to read it and should also include a statement that people with insurance may pay a different amount for the product. The rule takes effect in 60 days and the drug industry opposes the rule, which they say could sway patients away from certain medications and lead to more misinformation on the actual costs.
House Appropriations Committee approves $2 billion NIH increase. The House Appropriations Committee approved their fiscal year 2020 Labor, HHS, and Education Appropriations bill that includes a $2 billion increase in NIH funding. The Committee also includes critical report language on several GI research areas including inflammatory bowel disease, colorectal cancer screenings, early onset colorectal cancer, and the role of food as medicine in treating diseases. The bill also includes important language directing CMS to require Medicare Advantage plans to exclude from prior authorization requirements those services that align with evidence-based guidelines and have a high prior authorization approval rate. The language also calls for more transparency for MA plans with prior authorization so physicians are aware of what services require it.
Medical Nutrition Equity Act introduced in House. Rep. Jim McGovern, D-Mass., introduced H.R. 2501, the Medical Nutrition Equity Act, legislation that would mandate coverage of medically necessary foods for individuals with digestive and inherited metabolic disorders. AGA is supportive of this legislation that is critical for patients with digestive diseases and ensures their access to these lifesaving products.
The House of Representatives passed two bills aimed at speeding up the development of generics and biosimilars while the Trump administration finalized a rule to require drug companies to list the price of their products in their television ads.
The House passed two bills to address drug pricing. The House passed H.R. 1503, the Orange Book Transparency Act of 2019, legislation that would make changes to the FDA’s “orange” book to provide better information on brand drug and patent exclusivity. The orange book is used by doctors and pharmacists for information on generic drug approvals and availability. It is also used by generic drug manufacturers to make decisions on where to invest in research and development as it provides information on the exclusivity period for brand name drugs. Similarly, the House passed H.R. 1520, the Purple Book Continuity Act, legislation that would update FDA’s “purple” book on patents and exclusivity for biologics. These are the first bills of the 116th Congress to pass that address the costs of drugs.
The Administration finalizes rule on drug costs in advertising. The Trump administration finalized a rule that would require drug manufacturers to disclose prices on their products in television advertisements. Manufacturers must list a product’s monthly wholesale price or the cost of a typical treatment if it is greater than $35 for 30 days. The information must appear in text large enough for people to read it and should also include a statement that people with insurance may pay a different amount for the product. The rule takes effect in 60 days and the drug industry opposes the rule, which they say could sway patients away from certain medications and lead to more misinformation on the actual costs.
House Appropriations Committee approves $2 billion NIH increase. The House Appropriations Committee approved their fiscal year 2020 Labor, HHS, and Education Appropriations bill that includes a $2 billion increase in NIH funding. The Committee also includes critical report language on several GI research areas including inflammatory bowel disease, colorectal cancer screenings, early onset colorectal cancer, and the role of food as medicine in treating diseases. The bill also includes important language directing CMS to require Medicare Advantage plans to exclude from prior authorization requirements those services that align with evidence-based guidelines and have a high prior authorization approval rate. The language also calls for more transparency for MA plans with prior authorization so physicians are aware of what services require it.
Medical Nutrition Equity Act introduced in House. Rep. Jim McGovern, D-Mass., introduced H.R. 2501, the Medical Nutrition Equity Act, legislation that would mandate coverage of medically necessary foods for individuals with digestive and inherited metabolic disorders. AGA is supportive of this legislation that is critical for patients with digestive diseases and ensures their access to these lifesaving products.
Top AGA Community patient cases
Physicians with difficult patient scenarios regularly bring their questions to the AGA Community to seek advice from colleagues about therapy and disease management options, best practices, and diagnoses. In case you missed it, here are the most popular clinical discussions shared in the forum recently:
1. Crohn’s disease, infliximab and liver abscess (http://ow.ly/mTod50uyXCQ)
A 22-year-old Crohn’s patient presented to the hospital in septic shock with acute renal failure due to pyogenic liver abscess, which had ruptured into the peritoneal cavity. Member seeks consult from the AGA Community on treatment options given this serious infection.
2. EUS-guided cholecystoenterostomy with LAMS (http://ow.ly/IqLP50uyXLg)
A member poses the question: how long should the stent stay in?
3. Colorectal cancer surveillance in Crohn’s colitis and small duct PSC (http://ow.ly/tbe650uyXQh)
A member asks if you would continue yearly CRC surveillance on a patient with Crohn’s colitis with very limited colonic involvement in the ascending colon, who is currently in clinical remission. The patient also has small duct PSC with early cirrhosis.
Access these clinical cases and more discussions at https://community.gastro.org/discussions.
Physicians with difficult patient scenarios regularly bring their questions to the AGA Community to seek advice from colleagues about therapy and disease management options, best practices, and diagnoses. In case you missed it, here are the most popular clinical discussions shared in the forum recently:
1. Crohn’s disease, infliximab and liver abscess (http://ow.ly/mTod50uyXCQ)
A 22-year-old Crohn’s patient presented to the hospital in septic shock with acute renal failure due to pyogenic liver abscess, which had ruptured into the peritoneal cavity. Member seeks consult from the AGA Community on treatment options given this serious infection.
2. EUS-guided cholecystoenterostomy with LAMS (http://ow.ly/IqLP50uyXLg)
A member poses the question: how long should the stent stay in?
3. Colorectal cancer surveillance in Crohn’s colitis and small duct PSC (http://ow.ly/tbe650uyXQh)
A member asks if you would continue yearly CRC surveillance on a patient with Crohn’s colitis with very limited colonic involvement in the ascending colon, who is currently in clinical remission. The patient also has small duct PSC with early cirrhosis.
Access these clinical cases and more discussions at https://community.gastro.org/discussions.
Physicians with difficult patient scenarios regularly bring their questions to the AGA Community to seek advice from colleagues about therapy and disease management options, best practices, and diagnoses. In case you missed it, here are the most popular clinical discussions shared in the forum recently:
1. Crohn’s disease, infliximab and liver abscess (http://ow.ly/mTod50uyXCQ)
A 22-year-old Crohn’s patient presented to the hospital in septic shock with acute renal failure due to pyogenic liver abscess, which had ruptured into the peritoneal cavity. Member seeks consult from the AGA Community on treatment options given this serious infection.
2. EUS-guided cholecystoenterostomy with LAMS (http://ow.ly/IqLP50uyXLg)
A member poses the question: how long should the stent stay in?
3. Colorectal cancer surveillance in Crohn’s colitis and small duct PSC (http://ow.ly/tbe650uyXQh)
A member asks if you would continue yearly CRC surveillance on a patient with Crohn’s colitis with very limited colonic involvement in the ascending colon, who is currently in clinical remission. The patient also has small duct PSC with early cirrhosis.
Access these clinical cases and more discussions at https://community.gastro.org/discussions.
Continue your VAM conversations on SVSConnect
Conversations surrounding the 2019 Vascular Annual Meeting have begun on SVSConnect. Share what you learned at your favorite session, start a discussion about the Branding Initiative or reminisce about the ‘Vascular Spectacular’ gala. Keep the conversations going and connect with other attendees you met – or didn’t meet – at the conference. Simply log in with your SVS credentials to get started. Reach out to [email protected] or call 312-334-2300 with questions.
Conversations surrounding the 2019 Vascular Annual Meeting have begun on SVSConnect. Share what you learned at your favorite session, start a discussion about the Branding Initiative or reminisce about the ‘Vascular Spectacular’ gala. Keep the conversations going and connect with other attendees you met – or didn’t meet – at the conference. Simply log in with your SVS credentials to get started. Reach out to [email protected] or call 312-334-2300 with questions.
Conversations surrounding the 2019 Vascular Annual Meeting have begun on SVSConnect. Share what you learned at your favorite session, start a discussion about the Branding Initiative or reminisce about the ‘Vascular Spectacular’ gala. Keep the conversations going and connect with other attendees you met – or didn’t meet – at the conference. Simply log in with your SVS credentials to get started. Reach out to [email protected] or call 312-334-2300 with questions.
Provide feedback on Branding Initiative
The SVS Branding Initiative concepts were introduced at the Vascular Annual Meeting last week. We asked attendees to provide their feedback either at the SVS booth or through the event app. Input from members is vital in moving this forward, and we appreciate all who have shared their thoughts on the topic. If you did not have the opportunity to complete the survey, there is still time! All SVS members are encouraged to provide feedback until the survey closes on June 26. Take the survey here.
The SVS Branding Initiative concepts were introduced at the Vascular Annual Meeting last week. We asked attendees to provide their feedback either at the SVS booth or through the event app. Input from members is vital in moving this forward, and we appreciate all who have shared their thoughts on the topic. If you did not have the opportunity to complete the survey, there is still time! All SVS members are encouraged to provide feedback until the survey closes on June 26. Take the survey here.
The SVS Branding Initiative concepts were introduced at the Vascular Annual Meeting last week. We asked attendees to provide their feedback either at the SVS booth or through the event app. Input from members is vital in moving this forward, and we appreciate all who have shared their thoughts on the topic. If you did not have the opportunity to complete the survey, there is still time! All SVS members are encouraged to provide feedback until the survey closes on June 26. Take the survey here.
VAM on Demand Coming Soon
If you missed the Vascular Annual Meeting, would like to review some sessions or view the ones you missed, purchase VAM on Demand. The online library will hold audio and slide presentations of most sessions from the meeting. It will become available in four-six weeks, at which time a notification will be distributed. Attendees will pay $199 and non-attendees will pay $499. Contact the SVS Education Department for more information at [email protected].
If you missed the Vascular Annual Meeting, would like to review some sessions or view the ones you missed, purchase VAM on Demand. The online library will hold audio and slide presentations of most sessions from the meeting. It will become available in four-six weeks, at which time a notification will be distributed. Attendees will pay $199 and non-attendees will pay $499. Contact the SVS Education Department for more information at [email protected].
If you missed the Vascular Annual Meeting, would like to review some sessions or view the ones you missed, purchase VAM on Demand. The online library will hold audio and slide presentations of most sessions from the meeting. It will become available in four-six weeks, at which time a notification will be distributed. Attendees will pay $199 and non-attendees will pay $499. Contact the SVS Education Department for more information at [email protected].
Remain Connected on Connect
How have you managed a possible infected aortitis, a severe focal stenosis or a fractured carotid stent? Give your input in discussions about these topics, and more, on your online community, SVSConnect. If you attended VAM last week, continue the discussions with other attendees. All SVS members can participate in discussions – log in here with your SVS credentials. Reach out to [email protected] or call 312-334-2300 with questions.
How have you managed a possible infected aortitis, a severe focal stenosis or a fractured carotid stent? Give your input in discussions about these topics, and more, on your online community, SVSConnect. If you attended VAM last week, continue the discussions with other attendees. All SVS members can participate in discussions – log in here with your SVS credentials. Reach out to [email protected] or call 312-334-2300 with questions.
How have you managed a possible infected aortitis, a severe focal stenosis or a fractured carotid stent? Give your input in discussions about these topics, and more, on your online community, SVSConnect. If you attended VAM last week, continue the discussions with other attendees. All SVS members can participate in discussions – log in here with your SVS credentials. Reach out to [email protected] or call 312-334-2300 with questions.
Subscribe to SVS Student Newsletters
The SVS has recently re-vamped its newsletters geared towards future vascular surgeons. These provide residents, students and vascular trainees with up-to-date information on upcoming events, awards and scholarships, open positions and more. These are sent on a bi-weekly and monthly basis, depending on what content you are interested in. Learn more and subscribe here. They will also be posted on the SVS future vascular surgeon’s Twitter and Facebook.
The SVS has recently re-vamped its newsletters geared towards future vascular surgeons. These provide residents, students and vascular trainees with up-to-date information on upcoming events, awards and scholarships, open positions and more. These are sent on a bi-weekly and monthly basis, depending on what content you are interested in. Learn more and subscribe here. They will also be posted on the SVS future vascular surgeon’s Twitter and Facebook.
The SVS has recently re-vamped its newsletters geared towards future vascular surgeons. These provide residents, students and vascular trainees with up-to-date information on upcoming events, awards and scholarships, open positions and more. These are sent on a bi-weekly and monthly basis, depending on what content you are interested in. Learn more and subscribe here. They will also be posted on the SVS future vascular surgeon’s Twitter and Facebook.
Apply for the Research Career Development Travel Award
The SVS Foundation developed the Research Career Development Travel Awards program to develop strong leaders in vascular surgery research. Recipients of the award will be assigned SVS research mentors who will provide guidance and discuss academic career advancement. They’ll also receive financial support to be used for travel, hotel accommodations and registration expenses for a research course. Applicants must be an SVS Candidate or Active Member who’s completed postgraduate clinical training in vascular surgery and has been in practice no more than seven years. Apply before August 15 to be considered.
The SVS Foundation developed the Research Career Development Travel Awards program to develop strong leaders in vascular surgery research. Recipients of the award will be assigned SVS research mentors who will provide guidance and discuss academic career advancement. They’ll also receive financial support to be used for travel, hotel accommodations and registration expenses for a research course. Applicants must be an SVS Candidate or Active Member who’s completed postgraduate clinical training in vascular surgery and has been in practice no more than seven years. Apply before August 15 to be considered.
The SVS Foundation developed the Research Career Development Travel Awards program to develop strong leaders in vascular surgery research. Recipients of the award will be assigned SVS research mentors who will provide guidance and discuss academic career advancement. They’ll also receive financial support to be used for travel, hotel accommodations and registration expenses for a research course. Applicants must be an SVS Candidate or Active Member who’s completed postgraduate clinical training in vascular surgery and has been in practice no more than seven years. Apply before August 15 to be considered.
Cardiothoracic & Vascular Surgeons Providing Alternative Perspectives
Cardiothoracic and vascular surgeons will – together – head for the top during the Aortic Summit, from 2 to 4:30 p.m. Saturday.
The event is presented in collaboration with the Society of Thoracic Surgeons. A similar summit at the 2017 VAM attracted hundreds of surgeons.
Several topics important to both groups of surgeons will be examined from both the cardiothoracic and vascular perspectives, said Ali Azizzadeh, MD, co-moderator with Keith Allen, MD, a member of both SVS and the STS. The session is recommended by the Society for Vascular Nursing.
“We do look at issues in different ways,” said Dr. Azizzadeh said of vascular and cardiothoracic surgeons. “We all have different tools and skill sets. That’s why it’s good to look at an issue from both perspectives and also look at the devices that apply to the other’s field.”
Speakers will cover the latest indications for procedures in patients with aortic dissection, which will segue into discussion of access complications and other issues that can occur with devices. Topics also will include alternative and newer methods of access.
Speakers and attendees also will discuss the newest technology currently in trials, recently approved, or in investigation, worldwide, he said.
The two groups will collaborate, for what Dr. Azizzadeh believes is the first time, on pulmonary embolism. “This is a hot area for innovation,” he said. “There are lots of new techniques and procedures to address currently unmet needs. Medical centers around the country are assembling multidisciplinary teams, referred to as Pulmonary Embolism Response Team or PERT – to be able to take care of these sick patients. It’s a trend for the future.”
Tickets are required and are available at the registration counter. An additional fee applies: $75 for SVS Candidate members-in-training, nonmember medical students and vascular and general surgery residents, and allied health professionals; $100 for SVS Candidate members; $150 for SVS members and $200 for nonmember physicians.
Topics and speakers include:
• Optimal Management of Uncomplicated Acute Type B Aortic Dissection, Faisal Bakaeen, MD.
• Optimal Management of Chronic Type B Aortic Dissection, Adam Beck, MD.
• Alternate Non-Femoral Vascular Access for Large Endovascular Devices, Keith Allen, MD.
• Managing Vascular Access Complications, Ross Milner, MD.
• Innovative Devices: Cardiothoracic, by Grayson Wheatly III, MD.
• Innovative Devices: Vascular, by Ali Azizzadeh, MD.
• Pulmonary Embolism Teams: Cardiothoracic perspective, by Lishan Aklog, MD.
• Pulmonary Embolism Teams: Vascular perspective, by Naveed Saqib, MD.
A discussion period will follow each set of presentations.
“It’s going to be a great session to review the latest topics that apply to both cardiothoracic and vascular surgery,” said Dr. Azizzadeh.
Saturday, June 15
2-4:30 p.m.
Gaylord National, National Harbor 2
Aortic Summit
Cardiothoracic and vascular surgeons will – together – head for the top during the Aortic Summit, from 2 to 4:30 p.m. Saturday.
The event is presented in collaboration with the Society of Thoracic Surgeons. A similar summit at the 2017 VAM attracted hundreds of surgeons.
Several topics important to both groups of surgeons will be examined from both the cardiothoracic and vascular perspectives, said Ali Azizzadeh, MD, co-moderator with Keith Allen, MD, a member of both SVS and the STS. The session is recommended by the Society for Vascular Nursing.
“We do look at issues in different ways,” said Dr. Azizzadeh said of vascular and cardiothoracic surgeons. “We all have different tools and skill sets. That’s why it’s good to look at an issue from both perspectives and also look at the devices that apply to the other’s field.”
Speakers will cover the latest indications for procedures in patients with aortic dissection, which will segue into discussion of access complications and other issues that can occur with devices. Topics also will include alternative and newer methods of access.
Speakers and attendees also will discuss the newest technology currently in trials, recently approved, or in investigation, worldwide, he said.
The two groups will collaborate, for what Dr. Azizzadeh believes is the first time, on pulmonary embolism. “This is a hot area for innovation,” he said. “There are lots of new techniques and procedures to address currently unmet needs. Medical centers around the country are assembling multidisciplinary teams, referred to as Pulmonary Embolism Response Team or PERT – to be able to take care of these sick patients. It’s a trend for the future.”
Tickets are required and are available at the registration counter. An additional fee applies: $75 for SVS Candidate members-in-training, nonmember medical students and vascular and general surgery residents, and allied health professionals; $100 for SVS Candidate members; $150 for SVS members and $200 for nonmember physicians.
Topics and speakers include:
• Optimal Management of Uncomplicated Acute Type B Aortic Dissection, Faisal Bakaeen, MD.
• Optimal Management of Chronic Type B Aortic Dissection, Adam Beck, MD.
• Alternate Non-Femoral Vascular Access for Large Endovascular Devices, Keith Allen, MD.
• Managing Vascular Access Complications, Ross Milner, MD.
• Innovative Devices: Cardiothoracic, by Grayson Wheatly III, MD.
• Innovative Devices: Vascular, by Ali Azizzadeh, MD.
• Pulmonary Embolism Teams: Cardiothoracic perspective, by Lishan Aklog, MD.
• Pulmonary Embolism Teams: Vascular perspective, by Naveed Saqib, MD.
A discussion period will follow each set of presentations.
“It’s going to be a great session to review the latest topics that apply to both cardiothoracic and vascular surgery,” said Dr. Azizzadeh.
Saturday, June 15
2-4:30 p.m.
Gaylord National, National Harbor 2
Aortic Summit
Cardiothoracic and vascular surgeons will – together – head for the top during the Aortic Summit, from 2 to 4:30 p.m. Saturday.
The event is presented in collaboration with the Society of Thoracic Surgeons. A similar summit at the 2017 VAM attracted hundreds of surgeons.
Several topics important to both groups of surgeons will be examined from both the cardiothoracic and vascular perspectives, said Ali Azizzadeh, MD, co-moderator with Keith Allen, MD, a member of both SVS and the STS. The session is recommended by the Society for Vascular Nursing.
“We do look at issues in different ways,” said Dr. Azizzadeh said of vascular and cardiothoracic surgeons. “We all have different tools and skill sets. That’s why it’s good to look at an issue from both perspectives and also look at the devices that apply to the other’s field.”
Speakers will cover the latest indications for procedures in patients with aortic dissection, which will segue into discussion of access complications and other issues that can occur with devices. Topics also will include alternative and newer methods of access.
Speakers and attendees also will discuss the newest technology currently in trials, recently approved, or in investigation, worldwide, he said.
The two groups will collaborate, for what Dr. Azizzadeh believes is the first time, on pulmonary embolism. “This is a hot area for innovation,” he said. “There are lots of new techniques and procedures to address currently unmet needs. Medical centers around the country are assembling multidisciplinary teams, referred to as Pulmonary Embolism Response Team or PERT – to be able to take care of these sick patients. It’s a trend for the future.”
Tickets are required and are available at the registration counter. An additional fee applies: $75 for SVS Candidate members-in-training, nonmember medical students and vascular and general surgery residents, and allied health professionals; $100 for SVS Candidate members; $150 for SVS members and $200 for nonmember physicians.
Topics and speakers include:
• Optimal Management of Uncomplicated Acute Type B Aortic Dissection, Faisal Bakaeen, MD.
• Optimal Management of Chronic Type B Aortic Dissection, Adam Beck, MD.
• Alternate Non-Femoral Vascular Access for Large Endovascular Devices, Keith Allen, MD.
• Managing Vascular Access Complications, Ross Milner, MD.
• Innovative Devices: Cardiothoracic, by Grayson Wheatly III, MD.
• Innovative Devices: Vascular, by Ali Azizzadeh, MD.
• Pulmonary Embolism Teams: Cardiothoracic perspective, by Lishan Aklog, MD.
• Pulmonary Embolism Teams: Vascular perspective, by Naveed Saqib, MD.
A discussion period will follow each set of presentations.
“It’s going to be a great session to review the latest topics that apply to both cardiothoracic and vascular surgery,” said Dr. Azizzadeh.
Saturday, June 15
2-4:30 p.m.
Gaylord National, National Harbor 2
Aortic Summit
